" class="no-js "lang="en-US"> LegoChem Biosciences - Medtech Alert
Thursday, March 28, 2024
LegoChem Biosciences | Pharmtech Focus

LegoChem Biosciences

About LegoChem Biosciences

LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to the discovery, development, and commercialization of innovative medicines by leveraging our chemistry expertise to make conventional biologics more targeted and potent for the benefit of patients with diseases of highly unmet medical needs. We are advancing sustainable pipelines in therapeutic areas within antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).

Related Story

LegoChem Biosciences Signs License Agreement to Acquire First-in-class Antibody From Elthera

February 13 2023

LegoChem Biosciences announced on February 13, 2023 a license agreement with Elthera AG, a biotechnology […]

Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates

October 21 2021

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing […]